It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Camurus AB (CAMX) NPV

Sell:220.00 SEK Buy:221.00 SEK Change: 5.00 SEK (2.31%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Sell:220.00 SEK
Buy:221.00 SEK
Change: 5.00 SEK (2.31%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Sell:220.00 SEK
Buy:221.00 SEK
Change: 5.00 SEK (2.31%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

Contact details

Solvegatan 41
+46 (46) 2865730

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
11.78 billion SEK
Shares in issue:
54.24 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Per Wallstrom
    Independent Chairman of the Board
  • Fredrik Tiberg
    President, Chief Executive Officer, Director
  • Eva Pinotti-Lindqvist
    Chief Financial Officer
  • Torsten Malmstrom
    Chief Technical Officer
  • Annette Mattsson
    Vice President - Regulatory Affairs
  • Agneta Svedberg
    Vice President, Clinical Development & Pharmacovigilance
  • Fredrik Joabsson
    Chief Business Development Officer
  • Andrew McLean
    Vice President Corporate Development and Senior Counsel
  • Peter Hjelmstrom
    Chief Medical Officer
  • Richard Jameson
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.